Angiogenesis: Bench to bedside, have we learned anything?

Toxicologic Pathology

Volumn 34, Issue 1, 2006, Pages 3-10

  Lee, Seung ^a   Wykrzykowska, Joanna ^a   Laham, Roger ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Animal models; Clinical trials; Congestive heart failure; Ischemic heart disease; Myogenesis; Placebo effect

Indexed keywords

ALGINIC ACID; ANGIOPOIETIN; CHEMOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HEPARIN ALGINATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOVIRUS VECTOR; ANGIOGENESIS; ARTERY OCCLUSION; CARDIOMYOPATHY; CELL BASED GENE THERAPY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COLLATERAL CIRCULATION; CORONARY ARTERY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; MEDICAL RESEARCH; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CLINICAL TRIALS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE; ANIMALIA;

EID: 33644636139     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1080/01926230500499415     Document Type: Review

References (62)

1. AHA (2004). AHA statistics. AHA website 2004.
2. Asahara, T., and Isner, J. M. (2002). Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11, 171-8.
3. Battler, A., Scheinowitz, M., Bor, A., Hasdai, D., Vered, Z., Di Segni, E., Varda-Bloom, N., Nass, D., Engelberg, S., Eldar, M., et al. (1993). Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 22, 2001-6.
4. Bauters, C., Asahara, T., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., and Isner, J. M. (1994). Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. Am J Physiol 267, H1263-71.
5. Bauters, C., Asahara, T., Zheng, L. P., Takeshita, S., Bunting, S., Ferrara, N., Symes, J. F., and Isner, J. M. (1995). Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 21, 314-24; discussion 324-5.
6. de Feyter, P. J. (1992). PTCA in patients with stable angina pectoris and multivessel disease: is incomplete revascularization acceptable? Clin Cardiol 15, 317-22.
7. Deindl, E., Buschmann, I., Hoefer, I. E., Podzuweit, T., Boengler, K., Vogel, S., van Royen, N., Fernandez, B., and Schaper, W. (2001). Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 89, 779-86.
8. Doggrell, S. A. (2004). Sirolimus-versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. Expert Opin Pharmacother 5, 1431-4.
9. Folkman, J. (1998a). Angiogenic therapy of the human heart. Circulation 97, 628-9.
10. Folkman, J. (1998b). Therapeutic angiogenesis in ischemic limbs. Circulation 97, 1108-10.
11. Grines, C., Watkins, M., and Helmer, G. (2002). Angiogenic Gene Therapy Trial (Agent) inpatients with stable angina pectoris. Circulation 105, 1291-7.
12. Grube, E., and Buellesfeld, L. (2004). Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 5 Suppl 2, S3-8.
13. Grube, E., Gerckens, U., Muller, R., and Bullesfeld, L. (2002). Drug eluting stents: initial experiences. Z Kardiol 91(Suppl 3), 44-8.
14. Harada, K., Friedman, M., Lopez, J. J., Wang, S. Y., Li, J., Prasad, P. V., Pearlman, J. D., Edelman, E. R., Sellke, F. W., and Simons, M. (1996). Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 270, H1791-1802.
15. Hendel, R. C., Henry, T. D., Rocha-Singh, K., Isner, J. M., Kereiakes, D. J., Giordano, F. J., Simons, M., and Bonow, R. O. (2000). Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101, 118-21.
16. Hennebry, T. A., and Saucedo, J. F. (2004). "No-Option" Patients. A Nightmare Today, a Future with Hope. J Interv Cardiol 17, 93-4.
17. Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., Gibson, C. M., Bajamonde, A., Rundle, A. C., Fine, J., and McCluskey, E. R. (2003). The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107, 1359-65.
18. Henry, T. D., Rocha-Singh, K., Isner, J. M., Kereiakes, D. J., Giordano, F. J., Simons, M., Losordo, D. W., Hendel, R. C., Bonow, R. O., Eppler, S. M., Zioncheck, T. F., Holmgren, E. B., and McCluskey, E. R. (2001). Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 142, 872-80.
19. Hoye, A., Tanabe, K., Lemos, P. A., Aoki, J., Saia, F., Arampatzis, C., Degertekin, M., Hofma, S. H., Sianos, G., McFadden, E., van der Giessen, W. J., Smits, P. C., de Feyter, P. J., van Domburg, R. T., and Serruys, P. W. (2004). Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol 43, 1954-8.
20. Isner, J. M. (1996). Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc Med 1, 79-87.
21. Isner, J. M. (1997). Angiogenesis for revascularization of ischaemic tissues [editorial]. Eur Heart J 18, 1-2.
22. Isner, J. M., and Feldman, L. J. (1994). Gene therapy for arterial disease. Lancet 344, 1653-4.
23. Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., and Symes, J. F. (1996). Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-4.
24. Jones, E. L., Craver, J. M., Guyton, R. A., Bone, D. K., Hatcher, C. R. J., Riechwald, N., Sauvage, L. R., Wu, H. D., Kowalsky, T. E., Davis, C. C., Smith, J. C., Rittenhouse, E. A., Hall, D. G., Mansfield, P. B., Mathisen, S. R., Usui, Y., Bell, M. R., Bailey, K. R., Reeder, G. S., Lapeyre, A. C., Holmes, D. R. J., Cowley, M. J., Vandermael, M., Topol, E. J., Whitlow, P. L., Dean, L. S., Bulle, T. M., Ellis, S. G., Buda, A. J., Macdonald, I. L., Anderson, M. J., Strauss, H. D., David, T. E., Berman, N. D., Wang, F. L., Zhi, Q. H., Tang, Y. F., Bertelsen, C. A., Kjoller, M., Hoier-Madsen, K., Folke, K., and Fritz-Hansen, P. (1983). Importance of complete revascularization in performance of the coronary bypass operation. Am J Cardiol 51, 7-12.
25. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery. J Am Coll Cardiol 35, 10A.
26. Laham, R., Rezaee, M., Post, M., Novicki, D., Sellke, F., Pearlman, J., Simons, M., and Hung, D. (2000b). Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 292, 795-802.
27. Laham, R., Sellke, F., and Pearlman, J. (1998). Magnetic resonance blood-arrival maps provides acccurate assessment of myocardial perfusion and collaterization in therapeutic angiogenesis. Circulation 98, I-373.
28. Laham, R. J. (2005). Angiogenesis and Direct Myocardial Revascularization. Humana Press, Totowa, NJ.
29. Laham, R. J., Chronos, N. A., Pike, M., Leimbach, M. E., Udelson, J. E., Pearlman, J. D., Pettigrew, R. I., Whitehouse, M. J., Yoshizawa, C., and Simons, M. (2000c). Intracoronary basic fibroblast growth factor (PGP-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 36, 2132-9.
30. Laham, R. J., Garcia, L., Baim, D. S., Post, M., and Simons, M. (1999a). Therapeutic Angiogenesis Using Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Using Various Delivery Strategies. Curr Interv Cardiol Rep 1, 228-33.
31. Laham, R. J., Hung, D., and Simons, M. (1999b). Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clin Cardiol 22, I-6-9.
32. Laham, R. J., Li, J., Tofukuji, M., Post, M., Simons, M., and Sellke, F. W. (2003a). Spatial heterogeneity in VEGP-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg 17, 245-52.
33. Laham, R. J., Mannam, A., Post, M. J., and Sellke, F. (2001a). Gene transfer to induce angiogenesis in myocardial and limb ischaemia. Expert Opin Biol Ther 1, 985-94.
34. Laham, R. J., and Oettgen, P. (2003). Bone marrow transplantation for the heart: fact or fiction? Lancet 361, 11-12.
35. Laham, R. J., Post, M., Rezaee, M., Donnell-Fink, L., Wykrzykowska, J. J., Lee, S. U., Baim, D. S., and Sellke, F. W. (2005). Transendocardial and transepicardial intramyocardial FGF-2 administration: Myocardial and Tissue Distribution. Drug Metab Dispos, forth coming.
36. Laham, R. J., Post, M., Sellke, F. W., and Simons, M. (2000d). Therapeutic Angiogenesis Using Local Perivascular and Pericardial Delivery. Curr Interv Cardiol Rep 2, 213-7.
37. Laham, R. J., Rezaee, M., Post, M., Sellke, F. W., Braeckman, R. A., Hung, D., and Simons, M. (1999c). Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 27, 821-6.
38. Laham, R. J., Rezaee, M., Post, M., Xu, X., and Sellke, F. W. (2003b). Intrapericardial administration of basic fibroblast growth factor: myocardial and tissue distribution and comparison with intracoronary and intravenous administration. Catheter Cardiovasc Interv 58, 375-81.
39. Laham, R. J., Sellke, F. W., Edelman, E. R., Pearlman, J. D., Ware, J. A., Brown, D. L., Gold, J. P., and Simons, M. (1999d). Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100, 1865-71.
40. Laham, R. J., and Simons, M. (1999). Basic Fibroblast Growth Factor Protein for Coronary Artery Disease. In Handbook of myocardial Revascularization and Angiogenesis, pp. 175-87. Martin Dunitz Ltd, New York.
41. Laham, R. J., and Simons, M. (2000). Growth Factor Therapy in Ischemic Heart Disease. In Angiogenesis in Health and Disease (G. Rubanyi, Ed.), pp. 451-75. Marcel Decker, New York.
42. Laham, R. J., Simons, M., Pearlman, J. D., Ho, K. K., and Baim, D. S. (2002). Magnetic resonance imaging demonstrates improved regional systolic wall motion and thickening and myocardial perfusion of myocardial territories treated by laser myocardial revascularization. J Am Coll Cardiol 39, 1-8.
43. Laham, R. J., Simons, M., and Sellke, F. (2001b). Gene transfer for angiogenesis in coronary artery disease. Annu Rev Med 52, 485-502.
44. Lopez, J. J., Laham, R. J., Stamler, A., Pearlman, J. D., Bunting, S., Kaplan, A., Carrozza, J. P., Sellke, F. W., and Simons, M. (1998). VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 40, 272-81.
45. Marshall, D. J., Palasis, M., Lepore, J. J., and Leiden, J. M. (2000). Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer. Mol Ther 1, 423-9.
46. McNeer, J. F., Conley, M. J., Starmer, C. F., Behar, V. S., Kong, Y., Peter, R. H., Bartel, A. G., Oldham, H. N., Jr., Young, W. G., Jr., Sabiston, D. C., Jr., and Rosati, R. A. (1974). Complete and incomplete revascularization at aortocoronary bypass surgery: experience with 392 consecutive patients. Am Heart J 88, 176-82.
47. Mukherjee, D., Bhatt, D. L., Roe, M. T., Patel, V., and Ellis, S. G. (1999). Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am J Cardiol 84, 598-600, A598.
48. Nisanci, Y., Sezer, M., Umman, B., Yilmaz, E., Mercanoglu, S., and Ozsaruhan, O. (2002). Relationship between pressure-derived collateral blood flow and diabetes mellitus in patients with stable angina pectoris: a study based on coronary pressure measurement. J Invasive Cardiol 14, 118-122.
49. Pearlman, J. D., Laham, R. J., Post, M., Leiner, T., and Simons, M. (2002). Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis. Curr Pharm Des 8, 1467-96.
50. Pearlman, J. D., Laham, R. J., Simons, M., Gladstone, S., and Raptopoulos, V. (1997). Extent of myocardial collateralization: determination with three-dimensional elastic-subtraction spiral CT. Acad Radiol 4, 680-6.
51. Rana, J. S., Mannam, A., Donnell-Fink, L., Gervino, E. V., Sellke, F. W., and Laham, R. J. (2005). Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 95, 1456-9.
52. Rosinberg, A., Khan, T. A., Sellke, F. W., and Laham, R. J. (2004). Therapeutic angiogenesis for myocardial ischemia. Expert Rev Cardiovasc Ther 2, 271-83.
53. Ruel, M., Laham, R. J., Parker, J. A., Post, M. J., Ware, J. A., Simons, M., and Sellke, F. W. (2002). Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 124, 28-34.
54. Ruel, M., Wu, G. F., Khan, T. A., Voisine, P., Bianchi, C., Li, J., Laham, R. J., and Sellke, F. W. (2003). Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation 108(Suppl 1), II335-10.
55. Sato, K., Laham, R. J., Pearlman, J. D., Novicki, D., Sellke, F. W., Simons, M., and Post, M. J. (2000). Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg 70, 2113-8.
56. Sellke, F. W., Laham, R. J., Edelman, E. R., Pearlman, J. D., and Simons, M. (1998). Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 65, 1540-4.
57. Shie, J. L., Wu, G., Wu, J., Liu, F. F., Laham, R. J., Oettgen, P., and Li, J. (2004). RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol Chem 279, 25010-6.
58. Simons, M., Annex, B. H., Laham, R. J., Kleiman, N., Henry, T., Dauerman, H., Udelson, J. E., Gervino, E. V., Pike, M., Whitehouse, M. J., Moon, T., and Chronos, N. A. (2002). Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788-93.
59. Tofukuji, M., Metais, C., Li, J., Franklin, A., Simons, M., and Sellke, F. W. (1998). Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation 98, II242-6; discussion II247-8.
60. Udelson, J. E., Dilsizian, V., Laham, R. J., Chronos, N., Vansant, J., Blais, M., Galt, J. R., Pike, M., Yoshizawa, C., and Simons, M. (2000). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease [In Process Citation]. Circulation 102, 1605-10.
61. Waugh, J., and Wagstaff, A. J. (2004). The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 4, 257-268.
62. Xu, X., Li, J., Simons, M., Laham, R. J., and Sellke, F. W. (2001). Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg 121, 735-42.